Quality of life in patients with pemphigus receiving adjuvant therapy.

摘要: Summary Background.  Pemphigus has a strong effect on patients’ quality of life (QOL). Aim.  To analyze QOL and psychological well-being within patient groups, subdivided according to their different adjuvant treatments. Methods.  All adult patients with pemphigus enrolled in the study were assessed using Short Form (SF)-36, Skindex-29, General Health Questionnaire (GHQ)-12 for health status, dermatology-specific aspects, presence comorbidity, respectively. The population was into following treatment groups: (i) those who untreated or treated only corticosteroids (CS) at dose ≤ 5 mg/day (no treatment, NAT); receiving not CS also received either (ii) azathioprine (AZ), (iii) cyclophosphamide (CY), (iv) mycophenolate mofetil (MM) (v) rituximab (RTX). Results.  In total, 113 recruited. There no significant differences between subgroups SF-36 Skindex-29 results. However, GHQ, there large scores scoring > 4 points (GHQ+) < 4 (GHQ−), especially more ‘physical’ components QOL. overall observed proportion GHQ+ 33.6%. Conclusions.  We found impairment subgroups; however, we association psychiatric morbidity poorer each groups. This should be concern dermatologists, as is associated poor adherence dissatisfaction care.